title: The use of danazol in the management of chronic immune thrombocytopenic purpura.
abstract: Danazol has recently been reported to be an effective mode of treatment for patients with refractory immune thrombocytopenic purpura. Following a 3 month trial of danazol, only one of 10 patients experienced a sustained increase in platelet counts and two other patients had a transient improvement. While the drug was well tolerated, it does not appear to be particularly helpful in the management of these patients.
mesh_terms: D000328:Adult; D000368:Aged; D001327:Autoimmune Diseases / Q000097:blood / Q000188:drug therapy*; D002908:Chronic Disease; D003613:Danazol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011245:Pregnadienes / Q000627:therapeutic use*; D011696:Purpura, Thrombocytopenic / Q000097:blood / Q000188:drug therapy*
chemical_list: D011245:Pregnadienes; D003613:Danazol